B
Bullisch
Bullisch · 25%EBS
$7.49
Szenariopreis
$6.380
-0.711 (-11.14%)Zum Schluss
Loading chart…
- Hoch
- 6.730
- Eröffnung
- 6.640
- Volumengewichteter Durchschnittskurs
- 6.42
- Volumen
- 2.24M
- Marktkap.
- 365.76M
- Tief
- 6.151
- Umsatz
- 14.37M
- EV/EBITDA, TTM
- 2.76
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
KI-Analyse of Emergent BioSolutions Inc (EBS)
KaufenEmergent BioSolutions Inc is a good buy right now due to its recent price increase of 11.53% over the last five days, indicating positive momentum, and a current price of $7.06, which is significantly below the analyst price target of $10. However, the company has faced challenges, including a net loss of $180.2 million in Q2 2026, which is a major risk.
Analystenbewertungen (6)
+135.11% Aufwärtspotenzial
Kaufen
5 Kaufen
1 Halten
0 Verkaufen
Aktuell: 6.38
Tief
15.00
Durchschnitt
15.00
Hoch
15.00
JPMorgan
Untergewichten
—
2026-08-21
JPMorgan
2026-08-21
Kursziel
—
Untergewichten
H.C. Wainwright
Kaufen
$10
2026-08-10
H.C. Wainwright
2026-08-10
Kursziel
$10
Kaufen
H.C. Wainwright
Kaufen
$12
2026-03-09
H.C. Wainwright
2026-03-09
Kursziel
$12
Kaufen
JPMorgan
Übergewichten
—
2025-12-02
JPMorgan
2025-12-02
Kursziel
—
Übergewichten
Barclays
Übergewichten
—
2025-12-02
Barclays
2025-12-02
Kursziel
—
Übergewichten
Bewertungskennzahlen
Das aktuelle erwartete KGV von Emergent BioSolutions Inc (EBS) beträgt 22.99, verglichen mit dem 5-Jahres-Durchschnitt von 13.19.
Alphio-AI-Kursszenarien für EBS
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
2.010-06stocktwitsRussian Plague Scare Triggers Vaccine Stock Surge
7.009-24PRnewswirePomerantz LLP Investigates Securities Fraud Claims Against Emergent BioSolutions
7.008-27PRnewswireEmergent BioSolutions Under Investigation for Securities Fraud
7.008-19NewsfilterEmergent BioSolutions Under Investigation for Securities Violations
- 7.008-17Newsfilter
Emergent BioSolutions Under Investigation for Securities Violations
EBS FAQ – beantwortet von Alphio AI
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Emergent BioSolutions Inc is a good buy right now due to its recent price increase of 11.53% over the last five days, indicating positive momentum, and a current price of $7.06, which is significantly below the analyst price target of $10. However, the company has faced challenges, including a net loss of $180.2 million in Q2 2026, which is a major risk.
6 analysts cover EBS: 5 rate it Buy, 1 Hold and 0 Sell. The average price target is 15.00.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.